• 1
    Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 152633.
  • 2
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 3
    Font J, Cervera R, Ramos-Casals M, Garcia-Carrasco M, Sents J, Herrero C, et al. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum 2004; 33: 21730.
  • 4
    Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al, the European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 5-year period: a multicenter prospective study of 1,000 patients. Medicine (Baltimore) 1999; 78: 16775.
  • 5
    Ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti–double-stranded DNA antibody levels as a major predictor of disease exacerbation in systemic lupus erythematosus: a long-term, prospective study. Arthritis Rheum 1990; 33: 63443.
  • 6
    Bastian HM, Alarcon GS, Roseman JM, McGwin G Jr, Vila LM, Fessler BJ, et al, for the LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL. II: factors predictive of new or worsening proteinuria. Rheumatology (Oxford) 2007; 46: 6839.
  • 7
    Bastian HM, Roseman JM, McGwin G Jr, Alarcon GS, Friedman AW, Fessler BJ, et al, the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002; 11: 15260.
  • 8
    Mosca M, Chimenti D, Pratesi F, Baldini C, Anzilotti C, Bombardieri S, et al. Prevalence and clinico-serological correlations of anti-α-enolase, anti-C1q, and anti-dsDNA antibodies in patients with systemic lupus erythematosus. J Rheumatol 2006; 33: 6957.
  • 9
    Kalaaji M, Fenton KA, Mortensen ES, Olsen R, Sturfelt G, Alm P, et al. Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int 2007; 71: 66472.
  • 10
    Smeenk RJ, van den Brink HG, Brinkman K, Termaat RM, Berden JH, Swaak AJ. Anti-dsDNA: choice of assay in relation to clinical value. Rheumatol Int 1991; 11: 1017.
  • 11
    Bootsma H, Spronk PE, Ter Borg EJ, Hummel EJ, de Boer G, Limburg PC, et al. The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus: a prospective long-term observation. Ann Rheum Dis 1997; 56: 6616.
  • 12
    Ter Borg EJ, Horst G, Hummel E, Limburg PC, Kallenberg CG. Rises in anti-double stranded DNA antibody levels prior to exacerbations of systemic lupus erythematosus are not merely due to polyclonal B cell activation. Clin Immunol Immunopathol 1991; 59: 11728.
  • 13
    Ho A, Magder LS, Barr SG, Petri M. Decreases in anti–double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 23429.
  • 14
    Tseng CE, Buyon JP, Kim M, Belmont HM, Mackay M, Diamond B, et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 362332.
  • 15
    Linnik MD, Hu JZ, Heilbrunn KR, Strand V, Hurley FL, Joh T, and the LJP 394 Investigator Consortium. Relationship between anti–double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52: 112937.
  • 16
    Hahn BH. Antibodies to DNA [review]. N Engl J Med 1998; 338: 135968.
  • 17
    Lefkowith JB, Kiehl M, Rubenstein J, DiValerio R, Bernstein K, Kahl L, et al. Heterogeneity and clinical significance of glomerular-binding antibodies in systemic lupus erythematosus. J Clin Invest 1996; 98: 137380.
  • 18
    Vlahakos DV, Foster MH, Adams S, Katz M, Ucci AA, Barrett KJ, et al. Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int 1992; 41: 1690700.
  • 19
    Chan TM, Leung JK, Ho SK, Yung S. Mesangial cell-binding anti-DNA antibodies in patients with systemic lupus erythematosus. J Am Soc Nephrol 2002; 13: 121929.
  • 20
    Sabbaga J, Pankewycz OG, Lufft V, Schwartz RS, Madaio MP. Cross-reactivity distinguishes serum and nephritogenic anti-DNA antibodies in human lupus from their natural counterparts in normal serum. J Autoimmun 1990; 3: 21535.
  • 21
    Tojo T, Friou GJ. Lupus nephritis: varying complement-fixing properties of immunoglobulin G antibodies to antigens of cell nuclei. Science 1968; 161: 9046.
  • 22
    Winfield JB, Faiferman I, Koffler D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus: association of high avidity antinative DNA antibody with glomerulonephritis. J Clin Invest 1977; 59: 906.
  • 23
    Lambrianides A, Giles I, Ioannou Y, Mason L, Latchman DS, Manson JJ, et al. Arginine mutation alters binding of a human monoclonal antibody to antigens linked to systemic lupus erythematosus and the antiphospholipid syndrome. Arthritis Rheum 2007; 56: 2392401.
  • 24
    Deocharan B, Qing X, Lichauco J, Putterman C. α-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. J Immunol 2002; 168: 30728.
  • 25
    Jones DS, Hachmann JP, Osgood SA, Hayag MS, Barstad PA, Iverson GM, et al. Conjugates of double-stranded oligonucleotides with poly(ethylene glycol) and keyhole limpet hemocyanin: a model for treating systemic lupus erythematosus. Bioconjug Chem 1994; 5: 3909.
  • 26
    Weisman MH, Bluestein HG, Berner CM, de Haan HA. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 1997; 24: 3148.
  • 27
    Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 2001; 28: 25765.
  • 28
    Alarcon-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V, et al and the LJP 394 Investigator Consortium. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003; 48: 44254.
  • 29
    Coutts SM, Plunkett ML, Iverson GM, Barstad PA, Berner CM. Pharmacological intervention in antibody mediated disease. Lupus 1996; 5: 1589.
  • 30
    Sem DS, McNeeley PA, Linnik MD. Antibody affinities and relative titers in polyclonal populations: surface plasmon resonance analysis of anti-DNA antibodies. Arch Biochem Biophys 1999; 372: 628.
  • 31
    McNeeley PA, Iverson GM, Furie RA, Cash JM, Cronin ME, Katz RS, et al. Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients. Lupus 2001; 10: 52632.
  • 32
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 63040.
  • 33
    Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
  • 34
    Strand V, Aranow C, Cardiel MH, Alarcon-Segovia D, Furie R, Sherrer Y, et al, the LJP 394 Investigator Consortium. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 2003; 12: 67786.
  • 35
    Strand V, Crawford B. Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. Expert Rev Pharmacoeconomics Outcomes Res 2005; 5: 31726.
  • 36
    Wilmer WA, Rovin BH, Herbet CJ, Rao SV, Kumor K, Hebert LA. Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003; 14: 321732.
  • 37
    Wu T, Xie C, Bhaskarabhatla M, Yan M, Leone A, Chen SS, et al. Excreted urinary mediators in an animal model of experimental immune nephritis with potential pathogenic significance. Arthritis Rheum 2007; 56: 94959.
  • 38
    Eardley KS, Zehnder D, Quinkler M, Lepenies J, Bates RL, Savage CO, et al. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int 2006; 69: 118997.
  • 39
    Kowal C, Degiorgio LA, Lee JY, Edgar MA, Huerta PT, Volpe BT, et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A 2006; 103: 198549.
  • 40
    Lapteva L, Nowak M, Yarboro CH, Takada K, Roebuck-Spencer T, Weickert T, et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 250514.
  • 41
    Kowal C, DeGiorgio LA, Nakaoka T, Hetherington H, Huerta PT, Diamond B, et al. Cognition and immunity; antibody impairs memory. Immunity 2004; 21: 17988.